Cash Flow Statements for RAPT Therapeutics, Inc. (RAPT)

Add RAPT to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

RAPT Therapeutics, Inc.

Symbol

RAPT

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, South San Francisco

Sector

Healthcare

Industry

Biotechnology

Website

https://www.rapt.com

ISIN

US75382E1091

CIK

1673772

CUSIP

75382E109

UEI

-

LEI

-

Business Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor.